Abstract
Progress has been made over the last decade or so in the treatment and management of Wilson’s disease. This has come about in part through the increasing use of new drugs. Thus, zinc is now accepted as a standard therapy, and tetrathiomolybdate has been introduced, at least in an experimental setting, for the initial treatment of neurologic Wilson’s disease. But improved management has also come about through the increasing recognition of the risks of using penicillamine in the patient presenting with neurologic symptoms, and in the increasing awareness of the problems created by poor compliance.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Bremner, I., Mills, CF., Yong, B.W. (1982). Copper metabolism in rats given di-or trithiomolybdates. Journal of Inorganic Biochemistry, 16:109–119.
Brewer, G.J., et al. (1998). The Treatment of Wilson’s Disease with zinc XV. Long-term follow-up studies. Journal Laboratory Clinical Medicine. In Press.
Brewer, G.J., Johnson, V., Dick R.D., Kluin, K.J., Fink, J.K., Brunberg, J.A. (1996). Treatment of Wilson’s disease with ammonium tetrathiomolybdate: II. Initial therapy in 33 neurologically affected patients and follow-up on zinc therapy. Archives of Neurology, 53(10): 1017–1025.
Brewer, G.J., Dick, R.D., Johnson, V., Wang, Y., Yuzbasiyan-Gurkan. V, Kluin, K., Fink, J.K., Aisen, A. (1994). Treatment of Wilson’s disease with tetrathiomolybdate I. Initial therapy in 17 neurologically affected patients. Archives of Neurology, 51: 545–554.
Brewer, G.J., Yuzbasiyan-Gurkan, V., Johnson, V., Dick, R.D., Wang, Y. (1993a). Treatment of Wilson’s Disease with zinc: XII. Dose regimen requirements. American Journal of Medical Sciences, 305(4), 199–202.
Brewer, G.J., Yuzbasiyan-Gurkan, V., Johnson, V., Dick, R.D., Wang, Y. (1993b). Treatment of Wilson’s disease with zinc: XI. Interaction with other anticopper agents. Journal of the American College of Nutrition, 12(l),26–30.
Brewer, G.J., Yuzbasiyan-Gurkan, V. (1992). Wilson’s disease. Medicine, 71:139–164.
Brewer, G.J., Dick, R.D., Yuzbasiyan-Gurkan, V, Tankanow, R., Young, A.B., Kluin, K.J. (1991). Initial therapy of Wilson’s disease patients with tetrathiomolybdate. Archives of Neurology, 48: 42–47.
Brewer, G.J., Yuzbasiyan-Gurkan, V., Dick, R.D. (1990). Zinc therapy of Wilson’s disease: VIII. Dose response studies. Trace Elements in Experimental Medicine, 3:227–234.
Brewer, GJ, Hill, G.M., Prasad, A.S., and Dick, R.D. (1987a). Treatment of Wilson’s disease with zinc: IV. Efficacy monitoring using urine and plasma copper. Proceedings of the Society of Experimental Biology in Medicine, 7:446–455.
Brewer, G.J., Terry, C.A., Aisen, A.M., Hill, G.M. (1987b). Worsening of neurologic syndrome in patients with Wilson’s disease with initial penicillamine therapy. Archives of Neurology, 44:490–493.
Brewer, G.J., Hill, G.M., Prasad, A.S., Cossack, Z.T., Rabbani, P. (1983). Oral zinc therapy for Wilson’s disease. Annals of Internal Medicine, 99:314–320.
Food and Drug Administration. (1973 and 1974). Teratologic evaluation of FDA 71-49 (zinc sulfate). Food and Drug Research Laboratories, Inc. Prepared for Food and Drug Administration, United States Department of Commerce Publications PD-221 805, and PB 267.
Gooneratne, S.R., Howell, J.M., Gawthorne, J. (1981). An investigation of the effect of intravenous administration of thiomolybdate on copper metabolism in chronic CU-poisoned sheep. British Journal of Nutrition, 46:469–480.
Harper, P.L., Walshe, J.M. (1986). Reversible pancytopenia secondary to treatment with tetrahiomolybdate. British Journal of Haematology, 64:851–853.
Hill, G.M., Brewer, G.J., Prasad, A.S., Hydrick, C.R., Hartmann, D.E. (1987). Treatment of Wilson’s disease with zinc: I. Oral zinc therapy regimens, Hepatology, 7:522–528
Hoogenraad, T. (1996). Wilson’s disease. In Major Problems in Neurology, van Gijn, J., ed. (Philadelphia, Pennsylvania: W.B. Saunders Company).
Keen, C.L., Lonnerdal, B., Hurley, L.S. (1982). Teratogenic effect of copper deficiency and excess. In Inflammatory Diseases and Copper, Sorenson, ed., (Humana Press).
Mills, CF., El-Gallad, T.T., Bremner, I. (1981a). Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats. Journal of Inorganic Biochemistry, 14: 189–207.
Mills, CF., El-Gallad, T.T., Bremner, I., Weham, G. (1981b). Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate. Journal of Inorganic Biochemistry, 14:163–175.
Mjolnerod, O.K., Dommerud, S.A., Rasmussen, K., Gjeruldsen, S.T. (1971). Congenital connective tissue defect probably due to D-penicillamine treatment in pregnancy. Lancet I, 673–675.
Nazer, H., Ede, R.J., Mowat, A.P., Willaims, R. (1986), Wilson’s disease: clinical presentation and use of prognostic index. Gut, 27:1377-181.
Scheinberg, I.H. and Sternlieb, I. (1984). Wilson’s disease. In Major Problems in Internal Medicine, Smith, M.D., L.E., ed. (Philadelphia, Pennsylvania: W.B. Saunders Company).
Schouwink, C (1961). De Hepato-Cerebrale Degeneratie. Biemond, A., ed. (Arnhem, Amsterdam: G.W. Van Der Wiel and Company).
Shimon, I., Sela, B.A., Moses, B., Doley, E. (1993). Hemolytic episode in a patient with Wilson’s disease treated with zinc. Israel Journal of Medical Sciences, 29: 646–647, 1993.
Solomon, L., Abrams, G., Dinner, M., Berman, L. (1977). Neonatal abnormalities associated with D-penicillamine treatment during pregnancy. New England Journal of Medicine, 296: 54–55.
Walshe, J.M., Munro, N.A.R. (1995). Zinc-induced deterioration in Wilson’s disease aborted by treatment with penicillamine, dimercaprol, and a novel zero copper diet. Archives of Neurology, 52: 10–11.
Walshe, J.M. (1982). Treatment of Wilson’s disease with trientine (triethylene tetramine) dihydrochloride. Lancet, 2:1401–1402.
Walshe, J.M. (1956). Penicillamine. A new oral therapy for Wilson’s disease. American Journal of Medicine, 21: 487–495.
Yuzbasiyan-Gurkan, V., Grider, A., Nostran, tT., Cousins, R.J., Brewer, G. (1992). The treatment of Wilson’s disease with zinc: X. Intestinal metallothionein induction. Journal of Laboratory Clinical Medicine, 120:380–386.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Brewer, G.J. (1999). The Treatment of Wilson&’s Disease. In: Leone, A., Mercer, J.F.B. (eds) Copper Transport and Its Disorders. Advances in Experimental Medicine and Biology, vol 448. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4859-1_10
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4859-1_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7204-2
Online ISBN: 978-1-4615-4859-1
eBook Packages: Springer Book Archive